neoX Biotech to present on EGFR x cMET bispecific nanobody drug conjugates at the 2024 AACR
March 19, 2024
neoX is excited to participate in the 2024 American Associate of Cancer Research Annual Meeting (AACR) in San Diego, California, USA (April 5th-10th). During the conference, neoX will present the pre-clinical data on its NXV01 program, titled “Discovery and characterization of EGFR x cMET bispecific nanobody drug conjugates with potent anti-tumor activity”. See information of the AACR poster below:
neoX deployed its advanced computational and experimental platform to initiate the NXV01 program. This program involved the identification, optimization, and assembly of highly selective nanobodies (VHHs) targeting EGFR and cMET in a bispecific format. The lead candidates potently bound and inhibited cellular EGFR and cMET, and were effectively internalized into EGFR/cMET-expressing cells. After payload conjugation, corresponding nanobody drug conjugates (NDCs) demonstrated high homogeneity and thermal stability, which led to selective and potent anti-tumor activity in vitro and in vivo.
“The NXV01 program targets a well-established anti-cancer mechanism, yet offers a markedly differentiated drug profile from existing competitors.” said Dr. Yang Xie, neoX’s Senior VP of Oncology who will present the poster at the conference. “We remain committed to leveraging our computation-driven discovery engine to craft innovative, impactful therapies for cancer patients globally.”
Details of the presentation will be released at the conference. We invite you to stay connected for the latest updates.
About neoX
neoX is a biotech company that combines artificial intelligence (AI), state-of-the-art biophysics and high-throughput experimentation to innovate highly differentiated therapeutics for unmet medical needs. neoX is focused on the discovery of macromolecular and multi-specific drug modalities, through deep insights into dynamic protein-protein interactions (PPIs). We aspire to generate Fist-in-Class and/or Best-in-Class medicines through both in-house pipeline progression and co-development with strategic partners on the global stage. Company is headquartered in Beijing, China, with research teams also located in Shanghai, China, and Boston, USA.
NeoX is a clinical stage, next-generation biotech company that combines artificial intelligence (AI), state-of-the-art biophysical simulation and high-throughput experimentation to innovate highly differentiated therapeutics for unmet medical needs. NeoX is uniquely focused on the discovery of macromolecular and multi-specific drug modalities, through deep insights into dynamic protein-protein interactions (PPIs). We aspire to generate Fist-in-Class and/or Best-in-Class medicines through both in-house pipeline progression and co-development with strategic partners on the global stage. Company is headquartered in Beijing (China), with research teams also located in Shanghai (China) and Boston (USA). NeoX's AI/computation capabilities and deep insights into protein-protein interaction (PPI) have enabled us to build a comprehensive and highly differentiated pipeline focused on the following drug modalities:
· neoBiologics: Antibody/nanobody, cytokine and protein drugs of unique activity and selectivity profile
· neoDegrader: Targeted Protein Degradation (TPD) drugs guided by meta-PPI-based rational design and empowered by execution excellence in discovery of non-canonical small molecule drugs like PROTAC and Molecular Glue.
Currently, we have multiple antibody- and cytokine-based drugs and PROTAC degraders at the candidate-selection or IND-enabling stage. We are actively seeking out-licensing opportunities for these innovative assets and looking for reliable partners to establish long-term partnership.
Website：www.neoxbio.com
E-Mail：bd@neoxbio.com